![[U.S. Food and
Drug Administration]](https://webarchive.library.unt.edu/eot2008/20090118033449im_/http://www.fda.gov/icon/header.gif){kind=icon}
This is the retyped text of a letter from Purdue Pharma L.P. Contact
the company for a copy of any referenced enclosures.
June 14, 1996
The above titled OxyContin (Oxycodone HCl Controlled-Release) and MS Contin (Morphine Sulfate Controlled-Release) conversion calculators both feature four panels (A-D) with recommended conversion dosing from other oral, parenteral and transdermal opioids. A slide card is moved to display the recommended conversion dose on each panel. A small but unknown number of the slide cards for the OxyContin Tablets and for the MS Contin Tablets conversion calculators were not correctly cut. This defect could cause a misalignment of the recommended conversion dose which could be read as one level higher or lower than intended.
A misaligned reading could cause the recommended conversion dose to be potentially toxic in a very small number of patients. Therefore, ALL dosage conversion slide card calculators for BOTH OxyContin and MS Contin Tablets should be discarded at once.
New dosage conversion tables for OxyContin and MS Contin Tablets are enclosed to provide the correct recommended dosage conversion information for each product. If further information is required, please write to Paul D. Goldenheim, MD, Vice President, or call 1-203-853-0123.
Very Truly Yours
Paul D. Goldeheim, MD
Vice President
![[FDA Home Page]](https://webarchive.library.unt.edu/eot2008/20090118033449im_/http://www.fda.gov/icon/iconhome.gif){kind=icon}